Experimental gene therapy targets Parkinson's motor symptoms
NCT ID NCT04167540
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 31 times
Summary
This early-stage study tests whether a gene therapy called AAV2-GDNF is safe for people with Parkinson's disease. The treatment delivers a protein that helps protect brain cells involved in movement. Eleven adults with mild to severe Parkinson's will receive the therapy and be monitored for side effects and changes in motor symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ohio State University Medical Center
Columbus, Ohio, 43210, United States
-
University of California Irvine
Irvine, California, 92697, United States
-
University of California San Francisco
San Francisco, California, 94103, United States
Conditions
Explore the condition pages connected to this study.